COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial)
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The primary objective is to compare the efficacy and safety of infliximab plus methotrexate
to infliximab alone for the long-term control of signs and symptoms of Crohn's disease (CD)
in patients with symptoms that are persistent enough to require corticosteroid therapy.